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The goal of cancer immunotherapy is the generation of an
effective, stable, and self-renewing antitumor T-cell population.
One such approach involves the use of high-afﬁnity cancer-speciﬁc
T-cell receptors in gene-therapy protocols. Here, we present the
generation of functional tumor-speciﬁc human T cells in vivo from
genetically modiﬁed human hematopoietic stem cells (hHSC) using
a human/mouse chimera model. Transduced hHSC expressing an
HLA-A*0201–restricted melanoma-speciﬁc T-cell receptor were in-
troduced into humanized mice, resulting in the generation of
a sizeable melanoma-speciﬁc naïve CD8+ T-cell population. Follow-
ing tumor challenge, these transgenic CD8+ T cells, in the absence
of additional manipulation, limited and cleared human melanoma
tumors in vivo. Furthermore, the genetically enhanced T cells un-
derwent proper thymic selection, because we did not observe any
responses against non–HLA-matched tumors, and no killing of any
kind occurred in the absence of a human thymus. Finally, the trans-
duced hHSC established long-term bone marrow engraftment.
These studies present a potential therapeutic approach and an
important tool to understand better and to optimize the human
immune response to melanoma and, potentially, to other types
of cancer.
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Immune-based therapies, including the adoptive transfer oftumor-speciﬁc autologous T cells, have been used to target
melanoma and other cancers (1–6). These autologous T cells
have been generated either by ex vivo manipulation of antigen-
speciﬁc T cells with cytokines or by genetically engineering T
cells to exhibit strong antitumor responses (5–16). Recent clini-
cal studies have used chimeric antigen receptors to modify T
cells genetically to target and deplete leukemia cells (5, 6). Al-
ternatively, Morgan et al. (17) transduced autologous T cells ex
vivo with a vector expressing a natural T-cell receptor (TCR)
speciﬁc for the melanoma-associated antigen recognized by T-
cells 1 [MART-1(26-35)] epitope and reintroduced them into
patients, resulting in tumor regression in two of the 15 subjects
(17). This very promising approach has some drawbacks, how-
ever. The introduction of a TCR into peripheral T cells may lead
to the generation of autoreactive clones because of transgenic
TCR chain mispairing with endogenous TCR chains (18) that do
not undergo proper negative selection (19). Also, T cells require
extensive manipulation before transduction and thus may lose
some of their potency (4) and ability to become long-term
memory cells (20). Finally, peripheral blood T cells can provide
strong immune responses but generally are not long lived and
may not support a lasting therapy (9, 21). Some of these limi-
tations could be circumvented by the use of genetically modiﬁed
human hematopoietic stem cells (hHSC) to generate mature and
functional antigen-speciﬁc T cells. Studies using ovalbumin-
speciﬁc TCR-transduced murine hematopoietic progenitors
resulted in functional ovalbumin-speciﬁc murine T cells in vivo
(22, 23). Immune responses were elicited after vaccination with
an OVA-speciﬁc epitope; however, this was not a disease model,
so the ability to ameliorate disease could not be assessed. An-
other group transduced mouse progenitors with an HLA-DR4–
restricted TCR speciﬁc for melanoma (24). The resulting murine
transgenic T cells were functional against murine tumor cell lines
transduced with HLA-DR4, but it is unclear how this approach
would work in human cells and on human tumors.
The use of human progenitors to generate human transgenic
T cells has been restricted mainly to in vitro studies. Antigen-
speciﬁc human T cells have been developed in vitro using OP9
stromal cells expressing the human Notch ligand Delta-like 1 (25,
26). In this case, because of the lack of a functional thymus, these
cells did not undergo proper T-cell selection; the lack of selec-
tion could lead to the development of autoreactive clones.
Recently our group used severe combined immunodeﬁcient
(SCID)-hu mice bearing human thymus/liver (thy/liv) implants
(27–29) to generate HIV-speciﬁc cytotoxic T lymphocytes (CTLs)
from transduced hHSC (30). This approach resulted in the gen-
eration of HIV-speciﬁc transgenic T cells, but the lack of pe-
ripheral reconstitution in this model prevented the assessment of
in vivo T-cell functionality. In the studies presented here, we use
a modiﬁed version of the bone marrow/liver/thymus (BLT) hu-
manized mouse model (31, 32), which contains a human thymus,
allows long-term peripheral immune reconstitution, and is a very
effective model to test transgenic T-cell functionality in vivo (31,
32). In this model, we transplanted human hematopoietic pro-
genitors transduced with an HLA-A*0201–restricted, melanoma-
speciﬁc TCR. After transplantation, we observed high levels of
reconstitution with transgenic CTLs. The mice were challenged
with HLA-A*0201–matched and nonmatched human melanoma
tumors and were monitored for tumor reduction and/or clear-
ance. The majority of the mice possessing TCR-transgenic cells
cleared the HLA-A*0201+–matched tumors. Phenotypic analysis
of the MART-speciﬁc CTLs following tumor challenge revealed
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the presence of both central and effector memory CD8 T cells.
Finally, transduced human bone marrow cells were detected 4 mo
after implantation, suggesting long-term bone marrow re-
constitution in treated mice. Our results demonstrate that ge-
netically engineering autologous human hematopoietic pro-
genitors with disease-speciﬁc TCRs can lead to the generation of
long-lasting and functional cytotoxic T cells that could provide an
effective therapy against chronic conditions such as cancer.
Results
Generation of MART-1–Speciﬁc Transgenic CTLs. Based on our pre-
viously described (30) humanized mouse model, the SCID-hu
mouse, the generation of functional transgenic CD8 T cells from
modiﬁed hHSC was feasible. Nevertheless, despite the successful
generation of functional anti-HIV CD8+ T cells in the human
thymus, the lack of peripheral reconstitution in the SCID-hu
mouse precluded assessment of in vivo efﬁcacy.
To determine the in vivo antimelanoma activity of the transgenic
T cells, we used a modiﬁed version of the BLT humanized mouse
model (31, 32) that allows full immune reconstitution in the pe-
riphery and in multiple lymphoid tissues and mimics human im-
mune function (31, 32). In addition, transgenic lymphoid and
myeloid lineages can be generated from genetically modiﬁed
hHSC. Such a model would allow us to challenge the treated mice
in vivo and properly assess antitumor activity. The presence of
a human thymic implant ensures proper T-cell selection that would
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Fig. 1. The lentiviral vector and experimental mouse model used to generate MART-1–speciﬁc CTL. (A) A schematic diagram of the lentiviral vector used. The
MART-1TCR chains and the sr39tk reporter are joined by 2A self-cleaving peptides for optimal processing of the expressed polypeptide resulting in the
generation of mature proteins. (B) A schematic diagram on the modiﬁed BLT model used in these studies for the generation of chimeric mice carrying MART-
1–speciﬁc T cells. The thy/liv implant was reconstructed from transduced and nontransduced CD34 cells isolated from an HLA-A*0201 fetal liver. A fraction of
the transduced cells is frozen and injected into the irradiated mice 3 wk later. Mice then are assayed over a period of 12 wk. (C) The timeline of the ex-
perimental protocol. Brieﬂy, after mice were injected with transduced progenitors (step 4 in B), we allowed T-cell development and peripheral reconstitution.
Tumors generally were injected 1 or 2 wk later with 5 × 106 cells per injection. Starting 1 mo after tumor injection, tumor size and T-cell presence were
monitored for 6–8 wk; then mice were killed. The spleen, blood, thymic implant, bone marrow, and tumors were collected and assessed for transgenic T-cell
functionality. The ﬁgure shows the sites of tumor injections. M202 is an HLA*0201+MART+ cell line that could serve as a target for the transgenic CTL, and
M207 is an HLA*0201−MART+ cell line that could not. NSG, NOD scid gamma, (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ).
Vatakis et al. PNAS | December 20, 2011 | vol. 108 | no. 51 | E1409
M
ED
IC
A
L
SC
IE
N
CE
S
PN
A
S
PL
U
S
minimize the production of autoreactive T-cell clones. We con-
structed a lentiviral vector encoding the F5 MART-1 TCR and
optimized herpes simplex virus 1 thymidine kinase (HSV1-tk)
(sr39Tk), which can be used as a PET reporter to image T cells in
vivo (Fig. 1A) (33, 34). F5 MART-1 is an improved MART-1–
speciﬁc TCR displaying enhanced afﬁnity to the antigen and was
provided by the Rosenberg group from the National Cancer In-
stitute (Bethesda, MD) (35). In this system (Fig. 1B), we recon-
stituted the thy/liv implant with a mix of transduced and
nontransduced progenitors, followed by an i.v. injection of pre-
viously frozen autologous transduced progenitors (Fig. 1 B and
C). Control mice were generated similarly, using nontransduced
progenitors from the same donor. T-cell development and re-
constitution were monitored by repeated blood draws (Fig. 1 B and
C). In three independent experiments, 4–6 wk after progenitor in-
jection, we successfully generated high levels of mature circulating
CD8+ T cells that expressed the MART-1–speciﬁc TCR (Fig. 2 A
and C). Furthermore, we rarely detected the expression of the
MART-1 TCR in circulating CD4 T cells (Fig. 2 B and C), sug-
gesting that the transduced cells underwent the proper T-cell lin-
eage-commitment processes. Furthermore, when MART-1 TCR-
transgenic hHSC were introduced into human thy/liv implants that
were not HLA-A*0201 restricted, we did not detect MART-1 tet-
ramer+ CD8 cells in the periphery, indicating that appropriate
positive selection was required for generation of TCR-transgenic
mature cells (Fig. S1). These results also suggest that functional
TCR-transgenic T cells are not being generated in the murine
thymus and are consistent with our previous results using anti-HIV
TCRs (30). Finally the majority of circulating CD8+MART-1+ T
cells displayed a naïve T-cell phenotype (Fig. 2D).
In Vivo Assessment of Antitumor Responses. To assess the in vivo
efﬁcacy of the transgenic T cells, we challenged the mice with two
types of melanoma tumors, M202, an HLA-A*0201+MART+
cell line, that could serve as a target for the transgenic CTL, and
M207, an HLA-A*0201−MART+ line, that could not (Fig. 1C).
Following tumor injection, we monitored the presence of tumor-
speciﬁc CTLs and tumor sizes biweekly for 8 wk (Fig. 1C). Based
on physical measurements, in treated chimeric animals the target
M202 tumors regressed over time compared with the nontarget
M207 tumors, whereas in control mice, the growth of both
tumors was comparable (Fig. 3A).
Tumor size measurements can be masked by tissue scarring or
“dead space” resulting from tissue necrosis caused by the anti-
tumor immune response and resulting in the appearance of false-
positive tumor growth. Thus, to ensure that the tumors measured
were live tissues, we used PET imaging for [18F]-ﬂuorodeox-
yglucose ([18F]FDG) uptake in the second mouse cohort to
measure tumor metabolic activity by glucose uptake. To facilitate
imaging, the tumors were implanted on the left (M202) and right
(M207) mouse shoulder. As shown in Fig. 3B, we observed some
animals in which the M202 tumor was larger than the M207
tumor by physical measurement, but PET imaging revealed a
large dark spot suggesting dead tissue. When analyzed in ag-
gregate, we saw a statistically signiﬁcant decrease in tumor
metabolic activity in mice receiving transduced hHSC (Fig. 3 C
and D, and Movies S1, S2, S3, S4, S5, S6, S7, S8, and S9). More
speciﬁcally, when comparing the M202 and M207 tumors in mice
receiving transduced progenitors (treated mice), M202 tumors
were targeted in seven of the nine treated mice, and four of nine
mice cleared the M202 tumors (Fig. 3 C and D). The antitumor
response is speciﬁc to the M202 tumor, because M202 tumor
growth was unaffected in mice receiving nontransduced pro-
genitors from the same donor (control mice) (Fig. 3C). Fur-
thermore in the control mice, both M202 and M207 tumors
exhibited high levels of glucose uptake that were not statistically
signiﬁcantly different (Fig. 3C). Similarly, the glucose uptake
levels of the M207 (nontargeted) tumors were not signiﬁcantly
different between the treated and control mice (Fig. 3C). These
data, in conjunction with physical measurements of the tumors
(Fig. 3A), suggest that the two tumors initially grow comparably;
however transgenic HLA-A*0201–restricted CTLs speciﬁcally
kill HLA-A*0201+ tumors in treated animals. Furthermore, the
antitumor activity is likely caused by a speciﬁc response gener-
ated by the MART-transgenic CTLs rather than by nonspeciﬁc
or alloimmune activity. Together these data strongly demon-
strate that the reconstituted transgenic CTLs are functional and
effectively limit or clear HLA-matched tumor growth.
Detection of Tumor-Inﬁltrating Lymphocytes in Matched Tumors. To
conﬁrm the above observations further, we examined the pres-
ence of tumor-inﬁltrating lymphocytes in both the HLA-matched
and nonmatched tumors. To this end we used the sr39tk probe
([18F]ﬂuoro-3hydroxymethylbutyl)guanine; [18F]FHBG) (34) to
image the mice in vivo and also used ﬂow cytometric analysis of
the excised tumors to detect the presence of tumor-inﬁltrating T
lymphocytes (TILs). At the end point of our two experiments, we
excised, processed, and analyzed the tumors by ﬂow cytometry to
detect MART-1–speciﬁc TILs. We were able to detect speciﬁ-
cally the presence of CD45 expressing MART-1+ cells in a small
number of HLA-matched tumors, but these cells were absent in
non–HLA-matched tumors (Fig. 4A). This infrequent event was
attributed to the small number of CD45+ cells and transgenic T
cells relative to the size and number of tumor cells. To increase
the sensitivity of our assay, in a separate cohort of mice we used
PET scanning to image the mice in vivo to detect the presence of
transgenic T cells expressing the sr39tk gene. Mice were imaged
6 wk after tumor injection. At this time point tumors had not
grown signiﬁcantly in size, facilitating detection of TILs using
PET (34). As shown in Fig. 4B, there were statistically signiﬁ-
cantly higher numbers of transduced peripheral blood cells in the
M202 tumors than in the control M207 tumors. Thus, our results
suggest that the TCR-transgenic CTLs speciﬁcally targeted the
MHC-matched tumors, as conﬁrmed both by the increased levels
of reporter expression shown by PET imaging and ﬂow cyto-
metric analysis of tumor-cell suspensions.
Transgenic CTLs Demonstrate Antitumor Activity ex Vivo. After kill-
ing some of our mice, we looked at the functionality of the
transgenic CTLs ex vivo. In our ﬁrst experimental group, sple-
nocytes from each humanized mouse were assessed for CTL
activity against the M202 and M207 targets, following 5-d ex vivo
stimulation. As shown in Fig. 5A, the transgenic CTLs main-
tained their antitumor activity following in vitro manipulation.
We also wished to determine if antitumor killing activity oc-
curred without any in vitro manipulation (Fig. 5B). To this end,
we harvested splenocytes from our second cohort and performed
a direct CTL killing assay without additional ex vivo stimulation.
As shown in Fig. 5B, the MART-1–speciﬁc CTLs were able to
kill the speciﬁc HLA-A*0201+ targets effectively. Together,
these data suggest that these transgenic T cells exhibit high levels
of antitumor activity following in vivo exposure to melanoma
tumors without any additional manipulation ex vivo.
The high level of CTL activity exhibited by the MART-1–speciﬁc
CTLs was supported by the phenotypic characteristics of
CD45+CD3+CD8+MART-1+ cells in the spleens and blood. As
shown in Fig. 5C, there were signiﬁcantly higher levels of CD25-
expressing cells, suggesting the presence of activated T cells, in ani-
mals receiving TCR-transduced HSC than in control animals not
receiving the TCRs. In addition, in treated mice, we observed the
presence of naïve (CD45RA+CCR7+), central (CD45RA−CCR7+),
and effector (CD45RA−CCR7−) memory cells as well as terminally
differentiated (CD45RA+CCR7−) cells in the spleen, suggesting
that the tumor challenge resulted in antigen-induced CD8 T-cell
maturation (Fig. 5D). In contrast, in control mice, the CD8 T-cell
population was predominantly naïve. The presence of effector
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Fig. 2. Reconstitution levels and phenotype of MART-1–speciﬁc T cells after injection of genetically modiﬁed hHSC. One representative experiment is shown,
and each panel represents one individual mouse. Blood samples collected 4 wk after the introduction of transduced hHSC were analyzed by ﬂow cytometric
analysis for MART-1 TCR expression by tetramer, CD45, CD4, and CD8. The populations shown here are gated on CD45+ cells. Statistical signiﬁcance was
determined by a paired Student’s t test (P < 0.05). (A) Levels of CD8 T cells expressing the MART-1 TCR. Percentages shown in bold represent the fraction of
CD8 T cells that is tetramer+. (B) Expression of MART-1 TCR in CD4 T cells. Numbers shown in bold indicate the fraction of CD4 T cells expressing the MART-1
TCR. (C) A cumulative dot plot of the CD4 and CD8 T-cell populations in A and B expressing the MART-1 TCR. (D) Blood samples also were stained for CD62L
and CD27 to assess the maturation state of CD8+MART-1+ T cells. The majority of cells were CD62L+, suggesting a naïve phenotype.
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Fig. 3. MART-1–speciﬁc CTLs limit growth of MART-1/HLA-A*0201 melanoma tumors. (A) Surface measurements of tumors from representative mice of two
different experiments. The tumors were injected in the left [M202, circles (●)] and right [M207. squares (■)] shoulder. Control mice were transplanted with
autologous nontransduced CD34 cells. The tumors were measured 4, 6, and 8 wk after tumor challenge. The end point at week 10 was assessed by PET imaging.
(B) Shown is a representative mouse in which the M202 tumor (gray shading) is larger that the M207 tumor. However, PET imaging (red) indicates that glucose
uptake is higher in the M207 tumor and that the additional tissue seen in the M202 tumor is mostly necrotic. (C) Levels of FDG uptake by the M202 and M207
tumors in control and treated mice as assessed by PET imaging. Muscle serves as a background control. Statistical signiﬁcance was determined by one-way
ANOVA. (D) Representative PET images from different mice. The circles were added to facilitate the identiﬁcation of the M202 (Left) and M207 (Right) tumors.
Statistical signiﬁcance for all of the experiments (unless otherwise indicated) was determined by a paired Student‘s t test with signiﬁcant values set at P < 0.05.
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memory cells and terminally differentiated effectors can account for
the strong antimelanoma cytotoxic activity observed ex vivo.
In addition, data compiled from our second cohort of mice
showed a correlation between tumor metabolic activity and levels
of reconstitution or ex vivo cytolytic activity. Mice exhibiting a
higher percentage of CD8/MART-1+/TCR+ cells in spleen
cleared or limited tumor growth more efﬁciently than did mice
having less reconstitution of transgenic cells. Similarly, higher ex
vivo CTL activity correlated strongly with decreased tumor
growth and clearance of the tumors (Fig. S2 and Table S1).
Transduced Progenitors Stably Populated Mouse Bone Marrow. Fi-
nally, we examined the longevity of the transduced CD34 pro-
genitors in the bone marrow. Longevity is crucial because in a
clinical setting it would be beneﬁcial for the patient to have a
pool of progenitors replenishing the immune system with fresh
antitumor cells. Bone marrow cells from mice injected with
transduced and nontransduced progenitors were assayed for the
presence of integrated vector and the expression of the sr39tk
reporter. We detected presence of the lentiviral vector used to
transduce the progenitor cells by quantitative real-time PCR
(Fig. 6A). Because of the lack of CD3 expression on progenitor
cells, TCR should not be present on the cell surface. Thus, we
looked at the expression of the sr39tk reporter gene. Following
stimulation of progenitor cells with stem cell factor (SCF) and
megakaryocyte growth and development factor (MGDF), sr39tk
was expressed in the bone marrow samples with high levels of
vector present (Fig. 6B). Thus, the transduced CD34 cells stably
repopulated the bone marrow of the irradiated recipient mice.
Together these data suggest that this approach could result in a
long-term engineering of the immune system leading to a thera-
peutic effect in patients with advanced melanoma.
Discussion
The data presented in this study demonstrate the generation of
functional transgenic human T cells speciﬁc for melanoma from
genetically modiﬁed humanHSC in vivo. Unlike previous work, in
this study we used a mouse/human chimera model and used only
human tissues to generate and assess the feasibility and func-
tionality of a potential gene therapy protocol. This model can be
a platform for the study and development of effective therapeutic
interventions against melanoma and other chronic diseases.
Although previous studies have shown that one can use ge-
netically modiﬁed human progenitors to generate transgenic T
cells, these studies were done either in vitro or in vivo without
assessing in vivo functionality (25, 26, 30). A number of studies
have been able to generate mature mouse T cells from mouse
HSC (22–24). However, in the study by Yang et al. (22), the
progenitor cells were not directed against a disease-speciﬁc an-
tigen. A recent study engineered murine HSC to express an
HLA-DR4–restricted TCR against the melanoma tyrosine-re-
lated protein 1 antigen (24). Although these studies showed the
generation of functional antigen-speciﬁc murine T cells, the
absence of a human thymus raises questions about appropriate
negative selection for human antigens. Furthermore, the dis-
tinctions in human and murine lineage commitment and de-
velopment underscore the importance of developing models that
focus on genetically modiﬁed human progenitor cells (36).
In contrast to the above models, our studies establish the
utility of this approach in a fully humanized system. Using the
BLT model, we successfully generated high levels of naïve
MART-1–speciﬁc CD8+ T cells. We did not detect any MART-
1–expressing CD4+ T cells except in isolated cases. Furthermore,
we noted no expression of the MART-1 TCR on mature CD8+
cells in mice that had thy/liv implants that did not express the
HLA-A*0201 molecule. Thus, expression of the MART-1 TCR
predominantly in CD8+ T cells can be attributed to the presence
of a functional human thymus (thy/liv implant) that allowed
proper T-cell selection processes to take place. Interestingly, on
occasion we noted CD8−/CD4− cells expressing the MART-
speciﬁc TCR (Fig. 2). These cells were CD56+; thus we believe
they are natural killer T cells. Future studies will explore whether
these cells or the occasional MART TCR+ CD4 T cells men-
tioned above are functional against melanoma target cells.
In the BLT system described here, we were able to challenge
treated mice with HLA-matched and nonmatched tumors and
assess the functionality of the MART-1+CD8+ cells. Using both
physical measurements and imaging studies, we showed that the
transgenic T cells targeted and in many cases cleared the HLA-
matched M202 melanomas. The efﬁcacy of the antitumor re-
sponse was not inﬂuenced by tumor growth rates, because the
M202 and M207 tumors grew at a similar rate when injected in
mice transplanted with autologous but nontransduced hHSC.
This result suggests that the observed antitumor response is
linked directly to the MART-1–speciﬁc CD8+ T cells. Moreover,
Fig. 4. Detection of TILs in the matched M202 tumor. (A) Total tumor cells
were stained for CD45 andMART-1 tetramer and analyzed by ﬂow cytometry
to detect TILs. The data indicate percentage of CD45+ cells that are MART-1
TCR-positive by tetramer staining. The levels of CD45+ cells in these tumors
ranged from 0.4–0.5% of total cells. Shown are individual mice from one
representative experiment. (B) Mice were imaged using an sr39tk-speciﬁc
probe 6 wk after tumor injection to detect inﬁltration of transgenic T cells
intoM202 andM207 tumors. Tumors from the samemouse are matched with
the same symbol. Shown are six mice from one representative experiment.
Statistical signiﬁcance was determined by a paired Student‘s t test with sig-
niﬁcant values set at P < 0.05. %ID/g, injected dose per gram of body weight.
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the relative lack of clearance of the control tumors relative to the
HLA- A*0201–matched tumors both in vivo and ex vivo indicates
that antiallogeneic responses are not responsible for the antitu-
mor activity observed on the targeted M202 tumors. In contrast,
we did note some loss of tumormass in the control tumors (M207)
in animals receiving TCR-transgenic stem cells. We believe that
this limited regression is caused by bystander activation of an
allogeneic response, which was initiated subsequent to cytokine
expression by activation of MART-speciﬁc T cells.
Interestingly, we found that the transgenic CTLs maintained
cytolytic activity ex vivo without the need for additional manip-
ulation, such as cytokine and peptide stimulation, in culture. This
result suggested that a sizeable fraction of the MART-1–speciﬁc
T cells found in the spleens of the humanized mice maintained
an effector phenotype. Indeed, we observed a diverse distribu-
tion of naïve, memory (central and effector), and terminally
differentiated CD8+ T cells in spleen and blood of treated ani-
mals. Thus, the in vivo tumor challenge induced a signiﬁcant
immune response that led to normal antigen-driven CD8 T-
cell maturation.
Our studies also establish that transgenic human HSC have
long-term engraftment potential. Bone marrow samples from
treated mice had substantial levels of integrated vector and
expressed the reporter upon stimulation. This result is quite
crucial, because the replenishment of fresh tumor-speciﬁc CTLs
can help prevent tumor regression.
Engineered peripheral blood T cells have shown promise as
immune-based therapies to target cancer; however, their impact is
short term, and they can have potential side effects such as au-
toimmune reactions (9, 19). The approach described here pro-
vides an opportunity to develop a long-term therapy that uses the
immune system’s natural T-cell selection processes. In this study,
we have demonstrated as a proof of principle the therapeutic
efﬁcacy of a stem cell-based genetically enhanced immune re-
sponse against melanoma and established a viable and successful
model for testing new, alternative therapeutic approaches for
A B C
D
Fig. 5. Ex vivo testing and the phenotype of MART-1–transgenic CTL after in vivo tumor challenge. (A) Splenocytes from mice injected with transduced CD34
were pooled and stimulated ex vivo with MART-1 peptide (1μg/mL) and irradiated feeders. Five days later the cells were used in a CTL killing assay. (B) After
mouse culling, splenocytes were collected and used in a CTL assay without any ex vivo stimulation. Transgenic MART-1 CTL frommice injected with transduced
progenitors speciﬁcally killed the M202 targets but did not kill the M207− controls. Cell cytotoxicities are at an effector:target ratio of 10:1. “Control”
indicates splenocytes collected from mice that were injected with nontransduced hHSC and incubated with the M202 targets. Statistical signiﬁcance for all of
the experiments was determined by a paired Student’s t test with signiﬁcant values set at P < 0.05. (C) Samples from blood and spleens of killed mice were
collected and used in a FACS-based phenotyping of CD45+CD8+CD3+MART-1+ T cells. Control mice were mice injected with nontransduced autologous hHSC.
MART-1–expressing cells displayed higher levels of CD25. (D) From the same animals and cell population as in C, we also examined the maturation state of
MART-1 cells. The bar graph below indicates the averages from each group shown in the dot plots above and the statistically signiﬁcant differences between
the treated mice and the controls. Asterisks indicate statistical signiﬁcance. Statistical analysis of the averages (bar graphs) was determined by a Student’s
t test with signiﬁcant values set at P < 0.05 to compare the differences between the control and treated mice. For the dot plots, statistical signiﬁcance was
determined by one-way ANOVA (P < 0.05) comparing the different CD8 T-cell subpopulations.
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chronic diseases such as cancer; this model has closer relevance to
the human immune system and applicability for the study of fu-
ture therapies.
Methods
Construction of MART-Speciﬁc Lentiviral Vector. The lentiviral vector pF5-sr39tk
expressing the F5 TCR chains and the sr39tk reporter was constructed as pre-
viously described (37). The TCR chains and the reporter gene are separated by
picornaviral-derived 2A sequences that allow the expression of a polycistronic
mRNA and the generation of the three protein products (38). Lentiviral vector
stockswere producedby transfection of 293FT cells with the pF5-sr39tk, pCMV-
ΔR8.2-Δvpr (packaging construct), and pCMV-VSV-G (envelope) plasmids.
Isolation and Transduction of CD34 hHSC. Fresh human fetal liver was obtained
from Advanced Bioscience Resources Inc. The tissue was processed, and CD34
cells were puriﬁed as previously described (SI Methods) (30) and were
transduced (multiplicity of infection = 5) using retronectin (Takara Bio, Inc.).
Cells then were washed and used for the generation of the BLT mice. A
fraction of the transduced cells was frozen to be used in CD34 cell injections.
Humanized BLT Mice. Mice were generated as previously described (28, 32).
Three weeks after the generation of humanized BLT mice, the mice were
irradiated at 300 rad using a cobalt-60 source to remove endogenous cells.
Then the frozen transduced CD34 cells were thawed and injected. Mice were
bled 4 and 6 wk after injection to assess reconstitution. All animal protocols
were performed under the approval of the University of California, Los
Angeles (UCLA) Animal Research Committee.
Tumor Treatment andMeasurement. The tumor cell linesM202 andM207were
established from metastatic melanoma lesions under UCLA Institutional
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Fig. 6. Levels of bone marrow reconstitution. Shown is a representative experiment with three different mice. The control mouse was injected with non-
transduced autologous progenitors. (A) Bone marrow cells were used in a real-time PCR assay to detect the presence of our lentiviral vector. (B) Progenitor
cells were stimulated with SCF (50 ng/mL) and MGDF (100 ng/mL) and were used in a ﬂow cytometric assay to detect expression of sr39tk.
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Review Board approval #02–08-067 and have been previously described (39).
At the day of tumor injection, cells were harvested, split in 5 × 106 cell ali-
quots, and resuspended in 50 μL of medium and an equal volume of
Matrigel (BD Biosciences) to improve cell engraftment. Injections were done
s.c. Tumor sizes were measured by the use of a caliper every 2 wk.
PET and CT Imaging. MicroPET/CT scans were done using the microPET Inveon
scanner (Siemens Preclinical Solutions) and MicroCATII CT scanner (Siemens
PreclinicalSolutions). Forglucoseuptake,micewere fasted for4–6hbefore [18F]
FDG injection. For tracer injection and imaging, mice were anesthetized with
2% isoﬂurane. Imaging started 60min after an i.p. injection of 7.4MBq (80 μCi)
[18F]FDG or [18F]FHBG via tail vein. Additional details on PET and CT imaging
are included in SI Methods. All image analysis was done using OsiriX (Pixmeo,
Geneva, Switzerland) software.
Ex Vivo Functional Assays. Splenocytes from treated and untreated BLT mice
were cultured with irradiated (3,500 rads), peptide-coated (1 μg/mL)
174xCEM.T1 (T1) cells (a professional antigen-presenting cell line that ex-
press high levels of HLA-A*0201) or non–peptide-coated cells in the presence
of 20 IU/mL of IL-2. MART-1 (ELAGIGILTV) peptide was purchased from
Invitrogen. Five days later the effectors were used in a CTL killing assay
against the M202 and M207 targets. In some experiments the effectors were
used without stimulation. The CTL killing assay was carried out using the
LIVE/DEAD cell-mediated cytotoxicity kit (Invitrogen) (SI Methods).
Flow Cytometry. Cells were phenotypically analyzed using ﬂuorochrome-
conjugated monoclonal antibodies speciﬁc for human CD3 (BD Biosciences),
CD4, CD8, CD25, CD27, CD45, CD45RA, CD45 RO, CD56, CD57, CD62L and
CCR7 (Beckman Coulter). Tetramer-expressing cells were identiﬁed using
MHC Class I tetramer containing the MART-1 (26–35) peptide conjugated to
allophycocyanin or phycoerythrin (PE) (Beckman Coulter). sr39tk was detec-
ted using a thymidine kinase 1 antibody (EPR3193) (Abcam) and PE-conju-
gated goat anti-rabbit (Beckman Coulter). Cells were processed by a Coulter
FC500 instrument and results were analyzed FlowJo (TreeStar, Inc.) software.
Real-Time PCR Analysis. DNA from 106 bone marrow cells was extracted and
used in a quantitative real-time PCR to assess levels of integrated vector
(SI Methods).
Statistics. Statistical analysis tests were performed as indicated in the article
and ﬁgure legends. Data were analyzed with paired or unpaired Student’s t
test or one-way ANOVA and Bonferroni multiple post hoc comparisons. All
statistical analyses were performed with GraphPad Prism v5.0 (GraphPad
Software). Values with P < 0.05 were considered signiﬁcant.
Additional Methods. More detailed methods are given in SI Methods.
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